



ZEOTONE® PLUS CLINICAL TRIALS

Complete Study Data

OVERVIEW



A double-blind, prospective, multicentric, randomized, three-arm, clinical study to evaluate the efficacy, safety and tolerability of polyherbal formulation Zeotone® Plus in comparison with placebo and a formulation containing glucosamine and chondroitin sulphate in the treatment of osteoarthritis in adult subjects, was conducted.









OVERVIEW



Why was the study conducted?

Being an innovator & expert in Ayurveda, after years of clinical experience & research we created an Ayurvedic medicine & wanted to validate it using modern clinical trials to ensure the scientific community understands the efficacy and safety of our product Zeotone® Plus to make sure many more people benefit out of our medicine.





Who conducted the study?

CRO - Auros Health care R&D India Private Limited (AHC/179/RDD/CR/EE/17). The study was registered under the CTRI - (Registration number is (CTRI/2017/12/010838)





Where was the study conducted?

Centres of the study were;

- SMC Ortho & Trauma Clinic (No: 12/1, Violet Flats, Mogappair West, Chennai)
- S.V Multi Speciality Hospital #177(77), Rangarajapuram Main Road, Kodambakkam, Chennai)



Trial Subjects Enrolment

Enrolment of subjects was with strictly defined inclusion and exclusion criteria. Randomization & blinding was done into two treatment arms and a placebo arm in a 1:1:1 ratio.

SUBJECT GROUPS

Three groups were formed



Zeotone® Plus:

29 subjects





Inclusion Criteria

- Adults between 30 and 65 years of age with confirmed diagnosis or known history of osteoarthritis, with a moderately active lifestyle. (both sexes and ages inclusive)
- Subject with Grade II or III of Kellergen Lawrence (KL) Grade.
- Subject with pain (Pain Scale score ≥4) on walking in one or both knees 24 hours prior to screening.
- Subjects with BMI ≤30 at the time of screening.
- Subjects who are ambulatory, requiring but not currently receiving or not satisfied with anti-inflammatory or anti-analgesic drugs





SUBJECT GROUPS

Exclusion Criteria

- Subjects with known hypersensitivity to herbal investigational products or their constituents.
- Subjects with known hypersensitivity to NSAID, aspirin, COX-2 inhibitors and other analgesic medicine.
- Subjects who have had hyaluronic acid injections, up to 6 months prior to enrolment.
- Subjects who have had an Intra-Articular Steroid, up to 3 months prior to enrolment.
- Subjects with immuno compromised state

complications.

- Significant (requiring surgical correction) Valgus or Varus deformity of the knee, ligamentous laxity, or meniscal instability.
- Concomitant inflammatory or any other disease/ condition which may affect joints (e.g., rheumatoid arthritis, metabolic bone disease, psoriasis, gout, pseudogout, chondrocalcinosis etc.)
- History of sepsis in any joint or any clinical concern for a sub-acute infectious process in the target joint.

- History of surgery in the target joint.
- Planned surgery on any lower extremity joint.
- Clinically significant venous or lymphatic stasis is present in the leg(s).
- Clinically apparent tense effusion or inflammation at the target knee.
- Any musculoskeletal condition that would impede measurement of efficacy at the target joint
- Subjects with uncontrolled diabetes, hypertension, or congestive heart failure.

The following scales were used for baseline and outcome measures of efficacy. WOMAC (Western Ontario & McMaster universities arthritis index) VAS (Visual analogue scale) for the measurement of pain OOL (Quality of life questionnaire) Physicians Global Impression of Change

Reduction in WOMAC





Zeotone® Plus: 100% of Subjects have achieved a reduction of at least 20 in the WOMAC score from Visit 1 to Visit 4. (Z = 5.29, p = 0.000 < 0.05).

There was a mean reduction of 36% between the scores from Visit 1-4




Glucosamine + Chondroitin Sulphate: Only 54.5% Subjects have achieved a reduction of at least 20 in WOMAC score from Visit 1 to Visit 4. (Z = 0.43, p = 0.335 > 0.05).


There was only a mean reduction of 24% between Visits 1-4



Placebo 0% Subjects have achieved a reduction of at least 20 in WOMAC score from Visit 1 to Visit 4. (Z = -4.36, p ffi 1.000 > 0.05).

There was only a 6% reduction in WOMAC scores in the placebo group







- Zeotone® Plus Was 40% more effective than glucosamine and chondroitin in the management of osteoarthritis as evidenced by the WOMAC scale
- Zeotone® Plus was 143% more effective than placebo in the management of Osteoarthritis

Reduction in VAS





Zeotone® Plus: 93% of Subjects have achieved a reduction of at least 4 on the Pain Scale from Visit 1 to Visit 4. (Z = 4.54, p = 0.000 < 0.05).

There was a 70% reduction in pain for patients in the study group between Visits 1 and 4.




Glucosamine + Chondroitin Sulphate: Only 23% of subjects have achieved a reduction of at least 4 in Pain Scale from Visit 1 to Visit 4. (Z = -2.56, p = 0.995 > 0.05).


There was only 33% reduction in pain between Visits 1 and 4 in the control group.




Placebo: 0% Subjects have achieved a reduction of at least 4 in the Pain Scale from Visit 1 to Visit 4. (Z = -4.36, p = 1.00 > 0.05).

There was only 22% reduction in pain between Visits 1 and 4 in the placebo group.







- Zeotone® Plus was 72% more effective than Glucosamine and chondroitin in reducing pain due to Osteoarthritis.
- Zeotone® Plus was 104% more effective than Placebo in reducing pain due to Osteoarthritis.

Improvement in QoL





Zeotone® Plus: 100% of Subjects have achieved an improvement of at least 10 in QoL score from Visit 1 to Visit 4. (Z = 5.29, p = 0.000 < 0.05).

There was a mean increase of 69% in the Quality of Life of people in the Study group




Glucosamine + Chondroitin Sulphate: Only 45% of Subjects have achieved an improvement of at least 10 in QoL score from Visit 1 to Visit 4. (Z = -0.43, p = 0.665 > 0.05).


There was a mean increase of 47% in the Quality of Life of people in the Control group




Placebo: 0% Subjects have achieved an improvement of at least 10 in QoL score from Visit 1 to Visit 4. (Z = -4.36, p = 1.00 > 0.05).

There was only a 5% increase in the Quality of Life of people in the Placebo group







- Zeotone® Plus was 38% more effective than Glucosamine and chondroitin in improving the quality of life of patients.
- Zeotone® Plus was 172% more effective than Placebo in improving the quality of life of patients.



Zeotone® Plus: 100% subjects have achieved a score of 2 or 1 in "Physician's Impression of Change Scale" by end of treatment. (Z = 5.29, p = 0.000 < 0.05)



Glucosamine + Chondroitin Sulphate: Only 23% subjects have achieved a score of 2 or 1 in "Physician's Impression of Change Scale" by end of treatment.

(Z = -2.56, p = 0.995 > 0.05)



Placebo: 0% subjects have achieved a score of 2 or 1 in "Physician's Impression of Change Scale" by end of treatment (Z = -4.36, p = 1.00 > 0.05)

Recurrence Of Pain After Treatment



up to 4 weeks

Zeotone® Plus

The recurrence of pain and/or symptoms of osteoarthritis did not occur up to 4 weeks, after stopping treatment. According to the data analysed it is confirmed that 100% of the subjects achieved a Secondary End Point of 11-20% variation between end of treatment and the recurrence of pain/symptoms.

(Z = 5.29, p = 0.000 < 0.05).



Glucosamine & Chondroitin Sulphate:

The recurrence of pain and/or symptoms of osteoarthritis did not occur up to 3 weeks, after stopping treatment. According to the data analysed it is confirmed that 91% of the subjects showed >20% variation between the end of treatment and the recurrence of pain/symptoms.

(Z = -3.71, p = 1.000 > 0.05).



Placebo

The recurrence of pain and/or symptoms of osteoarthritis did not occur within 1 week, after stopping treatment. According to the data analysed, it is confirmed that 100% of the subjects showed >20% variation between the end of treatment and the recurrence of pain/symptoms.

(Z = -3.90, p = 1.000 > 0.05).

Other observations



No adverse events related to the drug reported



No statistically significant difference in LFT & RFT between Visits 1 & 4 in the study group



No statistically significant difference in CBC between Visits 1 & 4 in the study group



RESULTS: SUMMARY



Zeotone® Plus was 40% more effective than Glucosamine and Chondroitin in the management of osteoarthritis as evidenced by the WOMAC scale



Zeotone® Plus was 72% more effective than Glucosamine and Chondroitin in reducing pain due to Osteo-arthritis.



Zeotone® Plus was 38% more effective than Glucosamine and Chondroitin in improving the quality of life of patients.



Zeotone® Plus was more effective; with a final score of 1 or 2, indicating "Very Much Improved" from baseline as per Physician's Global Impression of Change, upon treatment for 3 months.

RESULTS: SUMMARY



Upon the end of treatment, the recurrence of pain/symptoms was seen;

- Only after 4 weeks for Zeotone® Plus
- After 3 weeks for Glucosamine & Chondroitin Sulphate
- Within 1 week for Placebo.



Zeotone® Plus was more effective than Glucosamine & Chondroitin Sulphate in sustaining the effect even post-treatment showing <20% variation between end of treatment and recurrence of pain/symptoms.



There were no adverse events reported and no difference in any safety parameters



It was concluded that Zeotone® Plus is better than the combination of Glucosamine and Chondroitin in the management of Osteoarthritis.



For further information write to:

AVN Ayurveda Formulations Pvt. Ltd.

175 Vilachery main road, Muniyandipuram, Madurai - 625004 customercare@avnayurveda.in | www.avnayurveda.com

Authentic Ayurveda...Modern Approach